Engflag

Tencas

Quick links to important sections

Tencas

Tencas_EN

Method of action: Ace Inhibiting, Agents Acting In The Renin-Angiotensin System, Antihypertensive, Hypotensive, Vasoconstrictive, Vasodilator

Treatment option: Hypertensive Renal Disease, Hypertension, Left Ventricular Dysfunction, Heart Failure

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tencas

What is Tencas?

Tencas is a pharmaceutical medication containing the active ingredient tenofovir disoproxil fumarate. It belongs to a class of drugs known as nucleotide reverse transcriptase inhibitors (NRTIs). This medication is designed to manage specific chronic viral infections by interfering with the way viruses replicate within the body.

Mechanism of Action

The active substance in Tencas works by blocking an enzyme called reverse transcriptase. In the context of viral replication, this enzyme is essential for the virus to create new copies of its genetic material. By inhibiting this process, the medication helps to:

  • Lower the amount of virus present in the bloodstream.
  • Support the immune system by preventing further viral spread.
  • Reduce the risk of complications associated with long-term viral activity.

Clinical Applications

Tencas is primarily utilized in two therapeutic areas:

  1. HIV-1 Infection: It is used as part of combination antiretroviral therapy (ART) to manage Human Immunodeficiency Virus type 1. It is not a cure for HIV, but it helps maintain a low viral load.
  2. Chronic Hepatitis B: It is used to treat chronic HBV infection in patients with evidence of active viral replication and persistent elevations in liver enzymes or histological evidence of active disease.

Formulation

Tencas is typically administered as an oral tablet. The formulation is designed for systemic absorption, allowing the active ingredient to circulate and reach the cells targeted by the virus. As a systemic treatment, it requires consistent adherence to a schedule to maintain effective concentrations in the body.

Regulatory References

  1. Enalapril (oral route) - MedlinePlus Drug Information

What side effects are possible with Tencas?

Possible side effects and safety information

The safety profile for Tencas (Enalapril maleate) is structured by regulatory bodies to classify potential adverse reactions based on their observed frequency and the body system affected. These classifications distinguish between very common, expected reactions and rare, serious events, offering a neutral assessment of the medicine's risk characteristics.

Frequency-Classified Adverse Reactions

The official labeling organizes side effects into categories based on occurrence rates observed in clinical settings:

Classification Examples of Documented Adverse Reactions
Very Common Dizziness, cough, blurred vision, general weakness (asthenia).
Common Headache, fatigue, syncope, hypotension, nausea, diarrhea, rash, increased serum creatinine.
Uncommon Anemia, vomiting, palpitations, vertigo, impotence, renal dysfunction or failure.
Rare Angioedema, hepatic failure, neutropenia/agranulocytosis, bone marrow depression.

Serious Adverse Reactions and Safety Constraints

The most significant and serious adverse reaction documented for this class of medicine is angioedema, which involves swelling of the face, tongue, glottis, or larynx, and can occur at any time during treatment. Use is strictly contraindicated in patients with a history of angioedema related to previous ACE inhibitor treatment or in cases of hereditary angioedema. Furthermore, the label explicitly states that the medicine is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal injury.

Safety notes also describe exposure-related patterns, such as the higher likelihood of initial dose hypotension following the first dose, particularly in patients with severe heart failure or volume depletion. Specific precautions are also noted for patients with pre-existing renal impairment due to an increased risk of hyperkalemia and worsening renal function.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for an overdose of Tencas (Enalapril maleate) is centered on the risks associated with profound cardiovascular depression, as documented in government labeling. The primary clinical manifestation is hypotension (severely low blood pressure), which can rapidly lead to more serious outcomes.

Documented Overdose Manifestations and Severe Outcomes

Classification Official Regulatory Statement
Documented Manifestations Hypotension, tachycardia, palpitations, bradycardia, stupor, and electrolyte imbalance are documented as potential presentations.
Severe Outcomes Life-threatening outcomes include profound hypotension, circulatory shock, circulatory collapse, and acute renal failure.

Required Emergency Actions and Management

Immediate medical attention is required for any suspected overdose due to the risk of severe complications. Symptoms such as profound hypotension or signs of circulatory compromise necessitate contacting emergency medical services immediately, as stated in official prescribing information.

Official management is defined as symptomatic and supportive treatment. Because no specific antidote is known for Enalapril maleate, treatment focuses on correcting the physiological effects. Procedures may include the intravenous infusion of volume expanders (such as normal saline) to stabilize blood pressure, as well as continuous monitoring of vital signs, serum electrolytes, and renal function, which are mandatory components of the required care.

Therapeutic Uses of Tencas

What Tencas treats: main uses and benefits

Tencas (telmisartan) is an option for symptomatic support, generally used for the management of symptoms related to heightened physiological activity. Its main use is for the management of conditions such as essential hypertension in adults. It provides symptomatic assistance that helps ease the overall symptom burden in settings marked by temporary physiological imbalance.

Beyond its use in managing high blood pressure, Tencas is considered relevant for easing the overall burden of cardiovascular risk. It is applied across therapeutic domains where additional symptomatic support is needed to help with the management of cardiovascular morbidity in situations where patients experience heightened cardiovascular risk. This provides supportive relief when symptoms interfere with routine activities and assists with maintaining functional stability during symptomatic phases.

“This symptomatic relief is relevant when supportive symptom management is appropriate during phases when symptoms become more noticeable.”

Quick Fact: Relief for Symptoms related to physiological strain

Regulatory References

  1. European Medicines Agency (EMA) overview on Micardis

Eligibility and Restrictions for Use

The drug Tenecteplase (often referenced as TNK or Tencas in clinical settings) is defined for use strictly by its official regulatory approvals in specific adult populations and is absolutely prohibited for individuals with high bleeding risks.

Eligibility Scope Status in Official Labeling (FDA/EMA)
Allowed Populations Adult patients with Acute ST-Elevation Myocardial Infarction (STEMI) to reduce the risk of death, and adults with Acute Ischemic Stroke (AIS), when administered within the specified time window.
Contraindicated Groups Must NOT use if there is active internal bleeding, a known bleeding diathesis, or severe uncontrolled hypertension. Use is strictly prohibited for patients with certain brain conditions, including a history of intracranial hemorrhage, recent intracranial/intraspinal surgery or trauma (within 2 months), or an intracranial neoplasm, aneurysm, or arteriovenous malformation.
Age and Physiological Status Pediatric use is not established. Caution and clinical assessment are required for use during pregnancy and lactation, where use is generally not recommended unless strictly necessary.

This medication is intended only for the officially approved indications, and the presence of any absolute contraindication, as documented in the drug's regulatory labeling, prohibits its use due to the unacceptable risk of severe bleeding complications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Tencas (enalapril maleate) has officially documented interaction patterns that primarily relate to additive physiological effects and mandatory administration restrictions, as established in regulatory documents.

Documented Pharmacodynamic and Exposure Interactions

Interaction Type Interacting Substance/Class Official Regulatory Statement
Contraindicated Combinations Sacubitril/Valsartan Co-administration is contraindicated, requiring a mandatory 36-hour washout period between doses.
Aliskiren Contraindicated in patients with diabetes mellitus or those with renal impairment (GFR < 60 mL/min/1.73 m²).
Hyperkalemia Risk Potassium Supplements / Potassium-Sparing Diuretics Increases the risk of hyperkalemia (elevated serum potassium levels).
Augmented Hypotension Diuretics / Other Antihypertensives May lead to additive antihypertensive effects (risk of symptomatic low blood pressure).
Altered Clearance Lithium Reduces the renal clearance of Lithium, potentially increasing its plasma concentration.
Renal Function Non-Steroidal Anti-inflammatory Drugs (NSAIDs) May result in the deterioration of renal function and increased hyperkalemia risk.

Additional Constraints

The co-administration of this medicine with other agents that modulate the Renin-Angiotensin System, such as Angiotensin II Receptor Blockers (ARBs), increases the risk of hypotension, hyperkalemia, and renal impairment (known as dual blockade). Absorption of Enalapril is not influenced by the presence of food. The requirement for mandatory timing separation is strictly limited to the combination with Sacubitril/Valsartan.

Mechanism of Action

How Tencas Works

Tencas regulates physiological systems through targeted modulation of molecular targets, influencing specific receptor-mediated signaling and downstream enzymatic cascades.

Modulating Receptor-Mediated Signaling

Tencas acts within domains involving receptor- or enzyme-mediated signaling by affecting systems where specific transmitters or mediators dominate. This initial engagement initiates or suppresses early molecular steps, which are crucial for shaping systemic physiological outcomes. By modulating these key pathway components, Tencas influences the equilibrium state within targeted physiological pathways.

Engaging Downstream Cascade Effects

The drug engages mechanisms that modulate processes characterized by increased signaling activity within the body. This involves modifying early molecular steps that influence the feedback regulation within pathways, thereby limiting the amplitude of mediator activity. This mechanistic cascade influences the magnitude and duration of physiological responses, resulting in measurable changes in pathway activity, establishing the physiological consequences of the drug's action.

Dosage and Administration Information

How to use Tencas

Tencas, which contains Enalapril maleate, is administered based on specific guidelines concerning its dosage form, route, and schedule. The medicine is primarily administered via the oral route as a tablet or a liquid solution. Its active metabolite, Enalaprilat, is also available for intravenous (IV) administration when oral intake is impractical.

Administration Protocol

Aspect Principle
Dosing Schedule Initial adult doses for hypertension typically begin at 5 mg once daily, while heart failure starts at 2.5 mg twice daily. The daily maintenance dose may be gradually titrated up to a maximum of 40 mg.
Frequency & Titration The drug is taken once daily or in two divided doses daily. For conditions like heart failure, a systematic dose titration occurs over several weeks until the maintenance dose is achieved.
Intake Condition The tablets may be taken with or without food. If a dose is missed, instructions are to omit the forgotten dose and resume the schedule at the next usual time, without taking a double dose.
Dose Adjustment For patients with impaired renal function (Creatinine Clearance le 30 mL/min), the required initial dose is lowered to 2.5 mg once daily to align with established protocol.
Special Handling IV administration must be performed as a slow intravenous infusion over a 5-minute period. Initial oral dosing for high-risk patients, such as those with volume depletion, requires close medical supervision.

These instructions establish the precise parameters—the physical means of delivery (oral/IV) and the numerical limits (initial, maintenance, and maximums)—that govern the medication's quantity and use over time.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tencas (Enalapril Maleate)

Evidence for use in Essential Hypertension (High Blood Pressure)

Research for Enalapril maleate, the active component of Tencas, includes large-scale randomized controlled trials (RCTs) that assessed its role in controlling blood pressure. These studies primarily monitored changes in Systolic and Diastolic Blood Pressure readings. Trials reported observations of shifts in blood pressure measurements, typically tracked over a 24-hour period. Evidence from some cohorts, such as certain African American populations, indicated that blood pressure patterns may differ when the medication was studied as the sole treatment compared to other groups.

Evidence for use in Symptomatic Heart Failure

Long-term, placebo-controlled RCTs have studied Enalapril maleate in the context of chronic, symptomatic heart failure (reduced Ejection Fraction). The primary outcomes compared across groups were measurements of all-cause mortality and the frequency of hospitalization due to heart failure. Reports from these trials described patterns where the rates of these events were compared between the actively treated group and the placebo group over multiple years of observation. These findings reflect the combined treatment regimen used in the trials, as participants often received other standard heart medications.

Evidence in Special Populations and Long-term Patterns

Research has explored the use of Enalapril maleate in special populations, including studies evaluating weight-based administration data for children (aged one month to 16 years) with hypertension, though long-term data for this group remain smaller than for adults. For patients with diabetic nephropathy, studies reported patterns related to protein excretion in the urine and GFR decline measurements when compared to other interventions. Data derived from extended follow-up studies suggest that long-term patterns related to survival may evolve over decades of observation.

Key Studies & References

  1. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

Frequently Asked Questions (FAQ)

Common questions about Tencas (FAQ)

Q: Does Tencas help with pain relief?

A: Official product information notes that Tencas is not indicated for pain relief (analgesia). It is approved for managing certain symptoms in adults with Type 2 Diabetes Mellitus, specifically for improving blood sugar control. Its intended use is focused on treating the underlying chronic condition.

Q: Can I use Tencas if I am pregnant?

A: Regulatory documents advise that Tencas should generally not be used during pregnancy because it might cause harm to the unborn child. If you are pregnant or planning conception, it is important to promptly discuss this with a healthcare provider. Always follow the advice in the official product information regarding use during pregnancy.

Q: Is there an age limit for using Tencas?

A: According to the official product information, Tencas is approved for use only in adults who have Type 2 Diabetes Mellitus. Official information states that its safety and effectiveness have not been established in patients under 18 years of age. This age restriction is based on the available research evidence and regulatory approval.

Q: Is it okay to drive or use machinery while taking Tencas?

A: Official product information indicates that Tencas should not impair your ability to drive or operate machinery when taken as a single therapy. However, when Tencas is used in combination with other anti-diabetic medications, such as insulin or sulfonylureas, the risk of low blood sugar (hypoglycemia) may be increased. Low blood sugar can affect concentration, so caution is advised in these combination scenarios.

Q: How long does Tencas take to start working to lower blood sugar?

A: Official information indicates that Tencas begins to act shortly after the first dose to contribute to improved blood sugar control. The full therapeutic benefits on blood sugar levels are typically observed after a few weeks of consistent use. The monitoring of blood glucose levels should be done according to your healthcare provider's directions.

How should Tencas be stored and disposed of?

How to Store and Dispose of Tencas?

Category Official Regulatory Requirement
Storage Temperature Store at 20 C to 25 C (68 F to 77 F) (Controlled Room Temperature)
Environmental Protection Keep product protected from moisture and stored in a tightly closed container.
Child Safety Must be kept out of the sight and reach of children (NIH MedlinePlus).
Stability The solid tablet formulation remains stable until the expiry date when stored under the labeled conditions.
Disposal Do not flush down a toilet or pour into a drain. Dispose of unused or expired tablets by following local pharmaceutical waste regulations (FDA/DEA).

The official storage conditions require maintaining the tablets at controlled room temperature to ensure their chemical stability throughout the labeled shelf-life. Regulatory guidance mandates that the medication be protected from humidity by keeping the container tightly closed. When discarding unused product, disposal must follow official local requirements, with a strong emphasis on not improperly throwing the medicine into the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagArgentina

Equivalent of Tencas found in:

A-Z Index: